Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218322 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of ATMX in Treating Adolescents With ADHD and SUD
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 108
- Enrollment target
NCT00218322: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00218322 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 108 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00218322, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 108 participants
- Enrollment target
Study Summary
Adolescents with attention deficit hyperactivity disorder (ADHD) often develop substance use disorders (SUD). The purpose of this study is to evaluate the effectiveness of atomoxetine in treating adolescents dually diagnosed with ADHD and SUD.
Interventions
- DRUG Placebo
- DRUG Atomoxetine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00218322
The ClinicalTrials.gov registry entry for NCT00218322 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00218322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00218322 about?
NCT00218322 is a clinical study titled "Effectiveness of ATMX in Treating Adolescents With ADHD and SUD". Adolescents with attention deficit hyperactivity disorder (ADHD) often develop substance use disorders (SUD). The purpose of this study is to evaluate the effectiveness of atomoxetine in treating adolescents dually diagnosed with ADHD and SUD.
What is the current status of trial NCT00218322?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 108 participants. The study started on 2004-09. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00218322?
The interventions under investigation include: Placebo (DRUG), Atomoxetine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00218322?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.